Treatment of Female Pattern Hair Loss with Oral Antiandrogens
Sinclair R, MD, at British Journal of Dermatology has written the Treatment of Female Pattern Hair Loss with Oral Antiandrogens article and writes "The authors present an open intervention study to assess if antiandrogen therapy is effective in the treatment of female pattern hair loss.
Eighty women were entered into the study, all of whom underwent clinical evaluation and biopsy of the central mid scalp to provide both clinical and histologic evidence of female pattern hair loss. Patients also had hematologic screening to exclude systemic lupus erythematosus, thyroid disease, zinc and iron deficiency, and hormone dysregulation.
Patients were then divided into 2 treatment arms. Forty women received spironolactone 200 mg daily. The other 40 women received cyproterone acetate, the dose of which was determined by the presence or absence of menopause. Twenty-two post-menopausal women received 50 mg daily, while 18 pre-menopausal women received 100 mg daily for 10 days of every month in combination with oral contraceptive pills. Sixteen months was the average treatment duration. Patients were not allowed to use topical minoxidil. At baseline and then every 6 months, photography of the frontal and vertex scalp was performed on each patient. Assessment of these photographs was completed by 3 clinicians, blinded as to patient information and to treatment regimen, using a rating scale of increased hair density, decreased hair density, or no change.
The frontal and vertex areas of the scalp were given independent ratings. Photographic assessment served as the primary outcome for efficacy. Clinical grading of the mid scalp using a standard scale was also done. Analysis of the data showed no difference between the 2 treatment arms so the authors combined the results of both arms. Forty-four percent of women had increased hair density in either the frontal or vertex areas, or both. Another 44% showed no increase or decrease in hair density.
Twelve percent showed decreased hair density in one or both areas. Variables such as menopausal status, family history of hair loss, thyroid function, duration of hair loss, and patient age showed no statistically significant difference regarding treatment response. However, women with advanced hair loss of the mid scalp and hence a mid scalp clinical grade of 3 or 4 did show a statistically significant difference in regards to response compared with those of lesser grades. Adverse effects of the 2 treatments were not discussed in the article."
Eighty women were entered into the study, all of whom underwent clinical evaluation and biopsy of the central mid scalp to provide both clinical and histologic evidence of female pattern hair loss. Patients also had hematologic screening to exclude systemic lupus erythematosus, thyroid disease, zinc and iron deficiency, and hormone dysregulation.
Patients were then divided into 2 treatment arms. Forty women received spironolactone 200 mg daily. The other 40 women received cyproterone acetate, the dose of which was determined by the presence or absence of menopause. Twenty-two post-menopausal women received 50 mg daily, while 18 pre-menopausal women received 100 mg daily for 10 days of every month in combination with oral contraceptive pills. Sixteen months was the average treatment duration. Patients were not allowed to use topical minoxidil. At baseline and then every 6 months, photography of the frontal and vertex scalp was performed on each patient. Assessment of these photographs was completed by 3 clinicians, blinded as to patient information and to treatment regimen, using a rating scale of increased hair density, decreased hair density, or no change.
The frontal and vertex areas of the scalp were given independent ratings. Photographic assessment served as the primary outcome for efficacy. Clinical grading of the mid scalp using a standard scale was also done. Analysis of the data showed no difference between the 2 treatment arms so the authors combined the results of both arms. Forty-four percent of women had increased hair density in either the frontal or vertex areas, or both. Another 44% showed no increase or decrease in hair density.
Twelve percent showed decreased hair density in one or both areas. Variables such as menopausal status, family history of hair loss, thyroid function, duration of hair loss, and patient age showed no statistically significant difference regarding treatment response. However, women with advanced hair loss of the mid scalp and hence a mid scalp clinical grade of 3 or 4 did show a statistically significant difference in regards to response compared with those of lesser grades. Adverse effects of the 2 treatments were not discussed in the article."
